PaxMedica (MEX:PXMD) Total Liabilities: MXN54.19 Mil (As of Sep. 2024)


MEX:PXMD PaxMedica Inc MEX:PXMD
20 GF Score
Price MXN15.69
View Full Analysis

What is PaxMedica Total Liabilities?

PaxMedica MEX:PXMD 20 Total Liabilities is MXN54.19 Mil as of Sep. 2024. GuruFocus rates MEX:PXMD with a GF Score™ of 20/100.

PaxMedica's Total Liabilities for the quarter that ended in Sep. 2024 was MXN54.19 Mil.

PaxMedica's quarterly Total Liabilities increased from Mar. 2024 (MXN28.26 Mil) to Jun. 2024 (MXN47.76 Mil) and increased from Jun. 2024 (MXN47.76 Mil) to Sep. 2024 (MXN54.19 Mil).

PaxMedica's annual Total Liabilities declined from Dec. 2021 (MXN220.69 Mil) to Dec. 2022 (MXN40.86 Mil) and declined from Dec. 2022 (MXN40.86 Mil) to Dec. 2023 (MXN38.96 Mil).

PaxMedica Total Liabilities Historical Data

* Premium members only.

The historical data trend for PaxMedica's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PaxMedica Total Liabilities Chart

PaxMedica Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial 2.32 114.42 220.69 40.86 38.96

PaxMedica Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 65.67 38.96 28.26 47.76 54.19
MEX:PXMD
20GF Score
PaxMedica Inc MEX:PXMD
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PaxMedica Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

PaxMedica's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=30.469+(0+1.7763568394003E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+8.487+0+0)
=38.96

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=96.414-57.458
=38.96

PaxMedica's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=44.343+(0+-1.7763568394003E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+9.845+0+0)
=54.19

Total Liabilities=Total Assets (Q: Sep. 2024 )-Total Equity (Q: Sep. 2024 )
=16.146--38.042
=54.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of MXN54.19 Mil mean?
PaxMedica (MEX:PXMD) has a Total Liabilities of MXN54.19 Mil as of Sep. 2024. The total amount of liabilities as recorded on a company's balance sheet. View historical data for PaxMedica and its competitors.
Is PaxMedica's Total Liabilities too high?
PaxMedica's current Total Liabilities is MXN54.19 Mil. Overall, PaxMedica has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does PaxMedica's Total Liabilities compare to BTAX and NBIO?
PaxMedica's Total Liabilities of MXN54.19 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for PaxMedica and its competitors. PaxMedica's current Total Liabilities is MXN54.19 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PaxMedica stock overvalued right now?
PaxMedica (MEX:PXMD) has a current Total Liabilities of MXN54.19 Mil. The current Total Liabilities is MXN54.19 Mil. PaxMedica's overall GF Score™ is 20/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For PaxMedica (MEX:PXMD), the current Total Liabilities is MXN54.19 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PaxMedica Business Description

Address 303 South Broadway, Suite 125, Tarrytown, NJ, USA, 10591
PaxMedica Inc is a clinical-stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and now with rising incidence globally due to the long term effects of SARS-CoV-2 (COVID-19). The company's product candidate under development is PAX-101, an intravenous formulation of suramin, which it is developing for multiple indications, including East African HAT, ASD, ME/CFS, and LCS.
20GF Score

Get the complete analysis for MEX:PXMD

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN15.69
Price